Lymphoma & Myeloma Clinical Trials
Last Updated: 09/23/2021
CAR T/Cellular Therapy
Lymphoma CAR T/Cellular Therapy
Previously Treated
2020-0168: A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4-CAR-T) in Subjects with Relapsed or Refractory T-Cell Lymphoma (TCL)
2020-1073 (CERTAIN-TESSCAR002): Phase 1 Study of CD30-directed Genetically Modified Autologous T cells (CD30 CAR-T) in Patients with Relapsed or Refractory CD30 Positive Non Hodgkins Lymphoma
2020-1263: Long-term Follow-up Protocol for Subjects Treated with Adicet Bio Allogeneic Gamma Delta T-cell Investigational Products
2020-0184 (ALLO647): A Single arm, open label, phase 1/2 study evaluating the safety, efficacy, and cellular kinetics/pharmacodynamics of allo-501A, Anti-CD19 allogeneic car t cell therapy, and allo-647, an anti-CD42 monoclonal antibody, in subjects with relapsed/refractor
2020-1137 (CD20): A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (?d) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
2020-0238 (CTX130): A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies
2020-0502 : An Observational Study to Evaluate A Wearable Temperature Monitoring Device in Subjects Receiving CAR - T Therapy
2020-1041 (ANTLER): A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)
2019-0940 (Zuma 18): A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects with Relapsed/Refractory B-Cell Malignancies
2019-1250 (JCAR017): A Phase II, open-label, single arm, multi cohort, multi center trial to evaluate the efficacy and safety of JCar017 in adult subjects with relapsed or refractory indolent B-cell Non hodgkin
2020-0120: Cardiovascular Events Among Adults Patients with Aggressive B-Cell Lymphoma Treated with Standard of Care Chimeric Antigen Receptor T Cell Therapy: A Single-Institution Experience
2019-0925 : Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in a Precision BioSciences, Inc., Clinical Study
2019-1051 : Pilot study of anakinra to mitigate CAR-T toxicity in subjects with relapsed or refractory large B-cell lymphoma
2018-1134 (LOXO-305): A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL)
2018-1049 (ALLO-501): Phase I/II study of ALLO-501, an anti-CD19 allogeneic CAR T cell therapy in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma
2017-0730 ( JCAR017): An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
2017-0946: Long-Term Follow-Up Protocol For Subjects Treated With Gene-Modified T Cells
2015-0529 (JCAR017): Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
2015-0569 : Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
Myeloma CAR T/Cell Therapy
Previously Treated
2018-0639 (KarMMA-3 BB2121): A Phase 3 Multicenter, Randomized, Open-Label Study to Compare Efficacy and Safety of BB2121 vs DARATUMUMAB (DARA) IN COMBINATION WITH POMALIDOMIDE (POM) AND LOW-DOSE DEXAMETHASONE (DEX) (DPd) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) (KarMMa-3)
2018-0572 (KarMMa-2): A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)
2017-1012 (AMG701): A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
2017-0494 (UCARTCS1): Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of A Single Dose of UCARTCS1 (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients with Relapse
2017-0444 (P-BCMA-101): Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)
Lymphoma Clinical Trials
Non Hodgkins Lymphoma
Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)
Newly Diagnosed
2017-0859 (ILyAD Vit D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-Free Survival in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy
Previously Treated
2021-0091: A Multicenter, Phase1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-cell Non Hodkins Lymphoma
2021-0109: A Phase 3, Randomized, Dounle-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab versus Lenalidomide in Addition to Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma
2021-0166: An Open-label, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-cell Non-Hodgkin Lymphoma
2020-0693: A Three-arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
2020-0272 : A phase 1B/3 double-blind, randomized, active-contrlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractor follicular lymphoma
2020-0177 (SWOGS1608): Randomized Phase II Trial In Early Relapsing Or Refractory Follicular Lymphoma
2020-0293 (GEN3009): Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma “A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
2020-0452: A Phase 1, First-in-human, Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants with NHL and CLL
2020-1029 : A Phase 1B Trial of Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (= 65) Patients with Primary CNS Lymphoma
2020-0639 (AZD4573) : A Modular Phase I/II, Open-label, Multicentre Study to AssessAZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
2020-0034 (aR2): A Phase II Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0313 (CG-806): A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0615 (FT516): A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
2019-0956 (CC-95251) : A Phase 1, Open-Label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed against SIRPa, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers
2019-1132 (FT596): A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase I/Ib Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0224 (Ibrutinib): Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
2014-0541: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B-cell Non Hodgkins Lymphoma
Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)
Newly Diagnosed
2021-0369: A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Poor Risk (IPI 3 to 5), Aggressive B-cell Lymphoma
2020-0686 : A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell Lymphoma
Previously Treated
2020-0263: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
2019-0605 (CPI-613): A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0999 (Hu5F9-G4): A Phase 1b/2 Trial of Hu5F9 G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0510 (NIVO): Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
2017-0626 (ASTX660): Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase 1 Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A, With or Without Single-dose Obinutuzumab Pre-treatment, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
2014-0539 (ACP-196): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
Mantle Cell Lymphoma
Previously Treated
2020-0638 (BGB-3111): An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B cell malignancies
2020-0858 (Acal-Rit): A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma
2020-1242 (LOXO-305): A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0421 (ACAL): A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma
2019-0469 (BGB-3111): A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
2019-0922 (ICP-022): A Phase I, Multicenter, Open-Label, Dose EscalationStudy of a Novel BrutonÂfs Tyrosine Kinase Inhibitor,ICP-022, in Patients with Relapsed/Refractory B-Cell
2019-1022 (Match): A Pilot Study of Interrogating biological Signaling Pathways Dysregulations and in vitro Screening with Personalized Therapies in resistant Mantle Cell Lymphoma (MCL) - the MCL Match Trial
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0935 (Venetoclax & Acalabrutinib): An open label, Phase II investigator initiated study of venetoclax and acalabrutinib in previously treated relapsed/refractory patients with mantle cell lymphoma (MCL)
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0051 (PDX): A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE trial
2017-0238: Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
2016-0914 (Ib-Smol): A Phase II Trial of Ibrutinib in previously untreated high risk smoldering mantle cell lymphoma (MCL)
2015-0372: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Hodgkin Lymphoma
Newly Diagnosed
2020-0460 (CD30.CAR-T): A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients with Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma
2019-1153 (SWOGS1826): A phase III, randomized study of nivolumab (OPDIVO) plus AVD or BRENTUXIMAB VEDOTIN (ADCETRIS) plus AVD in patients (AGE >/= 12 YEARS) with newly diagnosed advanced stage classical hodgkins lymphoma.
2018-1061: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Previously Treated
2020-0085 (PTCL): A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0981 (CD30 - PTCL): A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)
2019-0318 (cHL): A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
2018-0114 (DVD-AVD): A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previ
2017-0731 (PD-1 + ICE): A phase II trial of response-adapted second-line therapy for Hodgkin lymphoma using anti-PD-1 antibody nivolumab +/- ICE chemotherapy as a bridge to autologous hematopoietic cell transplant (NICE Trial)
T-Cell Lymphoma
Newly Diagnosed
2021-0058: A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-cell Lymphoma (PTCL) with less than 10% CD30 Expression
2021-0148: A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients with Relapsed Peripheral T-cell Lymphoma that Express KIR3DL2
2017-0927 (CD30+ PTCL): A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas
Previously Treated
2019-0755 (REDIRECT): A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
2018-1064 (TTI-622): A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advance Relapsed or Refractory Lymphoma or Myeloma
2017-0272 (MK-3475): A Phase I/II Study of Pembrolizumab (MK-3475) in Combination with Romidepsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Multiple Myeloma Clinical Trials
Newly Diagnosed
2021-0191 (DETER-SMM): EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
2020-0472 (CAEL-101 Amy): A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naive Patients with Mayo Stage IIIa AL Amy
2019-0556 (TAK-079): An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
2019-0304 (NDMM): A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
2018-0345 (Vaccine in SMM): A Personalized Vaccine for the Immune Prevention of Multiple Myeloma
Previously Treated
2020-0934: An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of BB2121 (IDE-CEL) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma
2020-1124: Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody)nin Patients with Relapsed or Refractory Multiple Myeloma
2020-0464 (CAEL-101): Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amylo
2020-0720 : A Non-Interventional, Multinational, Observational Study with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2020-0146 (PBCAR269A):A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, with or without nirogacestat, in Study Subjects with Relapsed/Refractory Multiple Myeloma
2020-0113 (MYD88):A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenstrom Macroglobulinemia (WM) whose Tumors Express Mutations in MYD88 and CXCR4
2020-0534 (APG-2575):A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenstrom Macroglobulinemia (WM)
2020-0103 (BFCR4350A):An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BFCR4350A In Patients With Relapsed Or Refractory Multiple Myeloma
2020-0610 (ION-251): A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma
2019-0945 (REGN5459): A Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
2019-0452 (RRMM): A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
2019-0499 (CT053): Open label, multi-center, phase 1b clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
2019-0624 (NKTR-255): A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
2019-1090 (NDMM): A Phase I, Open-label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
2018-0710 (P-BCMA-101): Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101
2018-0512 (D+B-Dex in R/R MM): A Phase 2 Study of Daratumumab, Bortezomab and Dexamethasone followed by Daratumumab, Ixaazomib, and Dexamethasone for Relapsed/Refractory Myeloma
2018-0285 (Ventelocla): A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11 14)-Positive Relapsed or Refractory Multiple Myeloma
2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies
2017-0618 (CC-92480 +Dex in R/R MM): A Phase I Multicenter, Open-label study to assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
2017-0243 (AL AMY): A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
2015-0148 : Phase II Trial Of Isatuximab With or Without Lenalidomide In Patients With High Risk Smoldering Multiple Myeloma
NCI10076 (AM232): A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
PA15-0575: Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies